SOPHiA GENETICS SA (SOPH)
SOPHiA GENETICS SA (SOPH) Stock Price, Analysis & Data
| Cours acheteur | n/a |
| Capitalisation boursière | 678.47M |
| Chiffre d’affaires (ttm) | 86.17M |
| Résultat net (ttm) | -80.88M |
| Bêta | 0.92 |
| EPS (ttm) | -1.16 |
| Ratio P/E (ttm) | n/a |
| P/E prévisionnel | -15.94 |
| P/B (ttm) | 8.17 |
| P/S (ttm) | 7.88 |
| Earnings Date | Nov 3, 2026 |
| Cours vendeur | n/a |
| Volume | 195,635 |
| Volume moy. (20D) | 320,725 |
| Ouverture | 7.73 |
| Clôture précédente | 7.62 |
| Fourchette du jour | 7.65 - 8.01 |
| Intervalle de 52 semaines | 3.10 - 8.01 |
| Analyste | n/a |
| Objectif de prix | n/a |
| Dividendes | n/a |
| Date ex-dividende | n/a |
À propos de SOPH
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as...
Performance financière
En 2025, le chiffre d’affaires de SOPHiA GENETICS SA s’élevait à 77.27M, soit une hausse de 18.56% par rapport aux 65.17M de l’année précédente. Le bénéfice s’élevait à -79M, soit une hausse de 26.41%.
États financiersSurprise sur les résultats
Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure
1 semaine il y a · Simply Wall St.
AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient AccessSOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on...
